5-fold that for CYP3A4
Jan 21, 2024 · Clarithromycin is a strong CYP3A4 inhibitor and this interaction may occur while using both drugs at their recommended doses
Inhibition of cytochrome P450 (CYP) 3A4 is the major cause of drug-drug interactions (DDI)
2
We assessed the differential effect of clarithromycin, a strong inhibitor of cytochrome P450 (CYP) 3A4 and P-glycoprotein, on the pharmacokinetics of a regular
Eight blood samples were collected within
The macrolide antibiotic clarithromycin is a potent mechanism-based inhibitor of both hepatic and intestinal cytochrome P450 3A (CYP3A) activity [ 1 ], thereby reducing the
Abstract
, erythromycin, clarithromycin Introduction
QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk)
Pharmacokinetic interactions often occur as a result of a change in drug metabolism
If co-administration of clarithromycin and colchicine is necessary in patients with normal renal and hepatic function, reduce the dose of colchicine
The aim of this study was to obtain an understanding of the time course of these changes
In this study, we quantitatively investigated the inhibition kinetics of MBI inhibitors, erythromycin and clarithromycin, on the CYP3A4 variants CYP3A4
Both erythromycin and clarithromycin decreased the activity of CYP3A4 in a time-dependent manner
These inhibitors were selected and were screened in triplicate on the plate on 3 separate occasions
1 μM clarithromycin reduces hepatic CYP3A4 by 61%, leading to a 2
Although mibefradil and isradipine inhibit CYP3A4 in vitro, only mibefradil, in usual clinical doses, markedly increased the peak plasma concentrations (1
Drug Metab Dispos
Therefore, it is not recommended to coadminister strong CYP3A4 inhibitors with everolimus (Food and Drug Administration, 2008)
7,
21 Mechanism-based inhibition of CYP3A4 is more likely to cause significant drug-drug interaction than reversible inhibition, as the body will not overcome this inhibition